Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease is a neurological disease that causes death of nerve cells that control voluntary muscles. Factors such, increase in incidence of ALS, strong pipeline molecule, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, opportunities and pipeline analysis assists the readers for understanding the ongoing trends in the global ALS treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global ALS treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global ALS treatment market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016. Factors such as increasing treatment awareness, strong pipeline molecules, rising geriatric population and recent approval of new treatment medication is expected to drive the growth of ALS treatment market globally. Currently, there is no cure for ALS however, treatments are available to control symptoms and prevent unnecessary complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole (Rilutek) and Edaravone (Radicava). Other medications are prescribe to control ALS symptoms such as muscle cramps and spasms, spasticity, constipation, fatigue, excessive salivation, excessive phlegm, pain, depression and sleep problems. It is studied that in the base year 2016, Riluzole (Rilutek) was major revenue generating segment due to high compliance because it is the only medication used in treatment of ALS which works by reducing levels of a chemical messenger in the brain (glutamate) that often present in higher levels in people with ALS. Patent expiry of Rilutek in 2013 has negatively impacted the growth of ALS treatment market. On the other hand, recently approve Radicava expected to show highest growth rate during forecast period due to its applicability and higher cost are expected to drive market growth during forecast period. Moreover expected launch of ALS treatment molecule such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, CK-2017357 (CK-357, tirasemtiv) would assist market growth during forecast period.

It is observed that, in the base year 2016, North America dominated the ALS treatment market in terms of revenue due to the factors such as upsurge in funding by government agencies and private organizations in healthcare system, increase in prevalence of the neurological diseases and higher treatment awareness are assisting market growth in North America. According to National ALS Registry, in year 2016, more than 12,000 people in the United States have a definite diagnosis of ALS, prevalence of 3.9 cases per 100,000 persons in the U.S. general population. According to National Organization for Rare Disorders (NORD), ALS is a rare disorder, approximately 5,000 new cases are diagnosed each year in the United States. Even though Riluzole is expensive, insurance policies such as Medicare, also the National Organization for Rare Diseases also support covers Riluzole. Furthermore Covis Patient Assistance Program helps U.S. citizens or residents who don't have a health care plan or have been denied coverage for treatment which is further driving the market growth in North America. It is estimated that, Asia Pacific will show highest growth rate during forecast period due to increasing healthcare awareness, increasing partnership of key players such as Biogen, Avicena, Mitsubishi Tanabe, and Sanofi with local manufacturer, populous countries and developing economic condition would fuel ALS treatment market growth.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Amyotrophic Lateral Sclerosis (ALS) Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Amyotrophic Lateral Sclerosis (ALS) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

• Riluzole
• Edaravone
• Other

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Amyotrophic Lateral Sclerosis (ALS) Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2030.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Amyotrophic Lateral Sclerosis (ALS) Treatment market?
• Which is the largest regional market for Amyotrophic Lateral Sclerosis (ALS) Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Amyotrophic Lateral Sclerosis (ALS) Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Amyotrophic Lateral Sclerosis (ALS) Treatment market worldwide?

This product will be delivered within 2 business days.